BiotechTube

IVA337 + Placebo + Empagliflozin

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NASH - Nonalcoholic Steatohepatitis

Conditions

NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2

Trial Timeline

Jun 29, 2022 → Jun 4, 2024

NCT ID
NCT05232071

About IVA337 + Placebo + Empagliflozin

IVA337 + Placebo + Empagliflozin is a phase 2 stage product being developed by Inventiva for NASH - Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05232071. Target conditions include NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2.

What happened to similar drugs?

0 of 5 similar drugs in NASH - Nonalcoholic Steatohepatitis were approved

Approved (0) Terminated (1) Active (4)
🔄IVA337 + PlaceboInventivaPhase 3
🔄MGL-3196 + PlaceboMadrigal PharmaceuticalsPhase 3
🔄Resmetirom + PlaceboMadrigal PharmaceuticalsPhase 3
❌Elafibranor + PlaceboGenfitPhase 3
🔄Aramchol free acid + PlaceboGalmed PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05232071Phase 2Completed

Competing Products

20 competing products in NASH - Nonalcoholic Steatohepatitis

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
AZD2693AstraZenecaPhase 1
29
AZD4076 + PlaceboAstraZenecaPhase 1
29
LIK066 + PlaceboNovartisPhase 2
35
Tropifexor (LJN452) + Cenicriviroc (CVC)NovartisPhase 2
35
Tropifexor + LicogliflozinNovartisPhase 2
27
LMB763 + PlaceboNovartisPhase 2
27
Tropifexor (LJN452) + PlaceboNovartisPhase 2
27
TRO19622 + PlaceboRochePhase 2
35
SEL + SIMGilead SciencesPhase 2
35
Seladelpar + PlacebosGilead SciencesPhase 2
27
Placebo + SIMGilead SciencesPhase 2
27
CilofexorGilead SciencesPhase 1
29
Firsocostat + FenofibrateGilead SciencesPhase 1
29
GS-9674 + Placebo to match GS-9674Gilead SciencesPhase 2
35